Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Collaboration
Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment
Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2018
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2016
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2014
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable